CARDIOTOXIC EFFECTS OF BTK INHIBITORS : PHARMACOVIGILANCE ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE

被引：0
|
作者：
Patel, Sagar [1 ]
Pandya, Krutarth K. K. [1 ]
Raval, Maharshi [1 ]
Patel, Akanksha [1 ]
Trivedi, Jaahnavee [1 ]
Patel, Riya [1 ]
Titus, Anoop [1 ]
Sattar, Yasar [1 ]
Victor, Varun [1 ]
Alraies, M. Chadi [1 ]
Bhakta, Shyam [1 ]
机构：
[1] Landmark Med Ctr, Woonsocket, RI USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2023年 / 81卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1744-044
引用
收藏
页码：2390 / 2390
页数：1
相关论文
共 50 条
  • [21] Adverse event signal analysis of remimazolam using the FDA adverse event reporting system database
    Liu, Hongtao
    Li, Zhaoyu
    Yan, Su
    Ming, Shaopeng
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2025, 69 (03)
  • [22] A Decade of Nintedanib: An Analysis of the FDA Adverse Event Reporting System Database
    Niranjan, S.
    Rao, A.
    Virk, S. T.
    Sarangdhar, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [23] Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
    Li, Yun
    Li, Hang
    Xiang, Zhongyuan
    HELIYON, 2024, 10 (06)
  • [24] Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021
    Wang, YanFeng
    Cui, Chanjuan
    Ren, Xiayang
    Dong, Xinran
    Cui, Wei
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [25] Analysis of Predictors of Adverse Events and Mortality Risk Associated With IL-6 Inhibitors: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database
    Fang, Meilin
    Li, Jinglin
    Zhuang, Boyang
    Liang, Weijie
    Wang, Ling
    Wang, Cunze
    Chen, Wujin
    Cai, Fangqing
    Ruan, Junshan
    Huang, Zhuiliang
    Jin, Yishun
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2025, 2025 (01)
  • [26] Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database
    Su, Zhengkang
    Huang, Zhengwei
    Chen, Xiaoyu
    Li, Xi
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [27] Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
    Li, Shangze
    Huang, Runcheng
    Meng, Yuanyuan
    Liu, Yijia
    Qian, Jiao
    Zou, Junjie
    Yang, Jun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [28] The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Caruso, I.
    Di Gioia, L.
    Di Molfetta, S.
    Caporusso, M.
    Cignarelli, A.
    Sorice, G. P.
    Laviola, L.
    Giorgino, F.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (11) : 2671 - 2678
  • [29] A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
    Zou, Fan
    Zhu, Chengyu
    Lou, Siyu
    Cui, Zhiwei
    Wang, Dan
    Ou, Yingyong
    Wang, Li
    Chen, Junyou
    Lan, Yuanbo
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [30] Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database
    Fan, Maoxia
    Niu, Kaibin
    Wu, Xiaoqi
    Shi, Hongshuo
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345